Compare Orion Office REIT Inc (ONL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs Sanofi SA — how do they compare? Orion Office REIT Inc trades at $2.17 (market cap $125.50M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 758.4× Orion Office REIT Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 33 Days and Sanofi SA for 94 Days on average.
| ONL | SNY | |
|---|---|---|
Market Cap | $125.50M | $95.18B |
Volume | 303,276 | 2,995,646 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $52.34 |
52-Week Low | $1.93 | $39.51 |
Typical Hold Time | 33 Days | 94 Days |
Enterprise Value | $542.43M | $114.48B |
Dividend Yield | 3.64% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.20, down 3.08% today, with a bearish technical signal. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics appear attractive with P/S of 0.88 and P/B of 0.2, but negative profitability metrics and high debt levels pose concerns. Recent news highlights strategic portfolio repositioning efforts.
Outlook remains challenging with ongoing revenue declines and negative margins, though deep valuation discounts may attract value investors. Key risks include high leverage, office sector exposure, and sustained profitability challenges. Analyst sentiment is mixed with 50% buy and 50% hold ratings.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
